Protagen to Help Biogen Idec Find Biomarkers for Multiple Sclerosis Therapy
The UNIarray platform will be used to find autoantibody patterns present in sera.!--h2>
Protagen will apply its UNIarray® technology and expertise in autoantibody research to support retrospective analysis of samples from a Biogen Idec clinical trial. Protagen is tasked with finding predictive and response biomarkers associated with multiple sclerosis (MS) therapy.
UNIarray is a platform for the development of diagnostics based on indication-specific autoantibody patterns in patient sera. These patterns have already been proven to be present in several autoimmune diseases as well as in cancer and neurodegenerative disorders. Protagen reasons that the systematic and indication-specific determination of autoantibody patterns will serve as a powerful basis to address hitherto unmet diagnostic needs.
“There is an acute need to discover possible response and non-response biomarkers in MS using genomic and proteomic level markers,” says Peter Schulz-Knappe, Ph.D., CSO of Protagen. “Autoantibody signatures play an increasingly important role as a technology platform that could be used to identify patients for optimized treatment efficacy and to monitor disease progression.”